What is known and objective: Chemo-and radiotherapy are therapeutic modalities often used in patients with malignant neoplasms. They kill tumour cells but act on healthy tissues as well, resulting in adverse effects. Oral mucositis is especially of concern, due to the morbidity that it causes. We reviewed the literature on the etiopathogenesis of oral mucositis and the activity of cannabidiol, to consider the possibility of its use for the prevention and treatment of oral mucositis. Methods: We searched the PubMed database and selected complete articles published in English that met the inclusion criteria for the period 1998-2016. The search terms 'cannabinoids', 'cannabidiol', 'oxidative stress', 'antioxidants' and 'oral mucositis' were used. Results and discussion: The control of oxidative stress may prevent and alleviate oral mucositis. Studies have demonstrated that cannabidiol is safe to use and possesses antioxidant, antiinflammatory and analgesic properties. What is new and conclusions: The literature on the use of cannabidiol in dentistry is still scarce. Studies investigating the use of cannabidiol in oral mucositis and other oxidative stressmediated side effects of chemotherapy and radiotherapy on the oral mucosa should be encouraged.
WHAT IS KNOWN AND OBJECTIVE
With an increase in life expectancy and an ageing population, the frequency of chronic non-communicable diseases such as cancer has been increasing. Consequently, there is a greater demand for antineoplastic treatments, which are responsible for major adverse effects. Oral mucositis (OM) is a complication commonly observed, particularly with radiotherapy (RT) of the head and neck area and with chemotherapy (CT). It is a painful and debilitating condition of varying severity. It is characterized by the presence of ulcerated lesions in the oral cavity, which usually leads to difficulty in eating and consequential loss of weight and malnutrition, and susceptibility to opportunistic infections. OM affects the quality of life of patients and can become a dose-limiting factor in treatment. [1] [2] [3] [4] [5] [6] There is considerable evidence that the cytotoxic effects of CT and RT result from physico-chemical reactions that lead to excessive production of free radicals (FR), which favours an oxidant-antioxidant imbalance and oxidative stress (OS). This could mediate the development of oral lesions and OM. 4, 5, [7] [8] [9] [10] [11] However, despite our understanding of the pathogenesis of this condition, its prevention and treatment are still considered a challenge to the dentist.
The use of cannabinoids, components of Cannabis sativa, in the treatment of complex diseases has been extensively investigated in different medical areas. Among the cannabinoids, cannabidiol (CBD) is the non-psychotropic cannabinoid of greatest abundance in the plant. 12 According to reported studies, CBD has antioxidant, anti-inflammatory and immunomodulatory properties and is devoid of psychoactive properties, and its minimal side effects make it safe for use in humans. [12] [13] [14] [15] This compound has shown promising results in the control of serious diseases such as epilepsy, Alzheimer's disease, multiple sclerosis, chronic pain, cachexia, diabetes and sepsis and in the treatment of various types of cancer. [16] [17] [18] [19] The use of CBD in the area of dentistry has been studied little, and its effects in the treatment of oral diseases are not well known. Nonetheless, considering its properties, mechanisms of action and favourable results in treating other complex diseases, it is believed that it can exert a positive therapeutic effect on some pathologies that are still challenging for the oral surgeon, for example OM.
The purpose of this review was to evaluate the therapeutic viability of CBD on the basis of scientific publications that discuss its mechanism of action, suggesting possibilities for future investigations regarding the use of this compound in dentistry.
METHODS
Accordingly, we carried out a review of the literature on the subject in the PubMed database. We used the keywords 'cannabinoids', 'cannabidiol', 'oxidative stress' and 'oral mucositis' to search for full articles published in English from 1995 to 2016. Additional papers were obtained from the reference lists in the 'hits'. Classic and more recent studies covered mechanisms of action, indications of use and possible future uses of CBD as well. Also included were publications regarding the aetiology, clinical features and forms of treatment of OM.
RESULTS

Oral mucositis
OM is frequently observed in patients receiving antineoplastic therapies. It occurs in about 30%-70% of patients treated with RT of the head and neck area and in 40%-80% of patients undergoing CT. When the two modalities are combined, the incidence of these lesions tends to increase, ranging from 50% to 100%. 3, 6, 20, 21 OM manifests as erythema of the oral mucosa or even extremely painful ulcerations. Its severity has been determined by various classifications, where the one recommended by the World Health of Organization (WHO) is the most widely used today. This takes into consideration clinical criteria, such as the presence and absence of injury, and subjective criteria, such as the presence of pain and ability to eat (Table 1) . Its clinical features vary according to the type of cancer therapy used and the health of the patient. 3, 6, 21, 22 Episodes of OM can greatly affect the quality of life of patients as well as the course of their cancer treatment. Oral pain is a common symptom, making it difficult or impossible to eat, leading in some cases to malnutrition. Moreover, resultant oral lesions are a port of entry for opportunistic pathogens, leading to infections that may require antibiotics, hospitalization and even discontinuation of cancer treatment. In addition to clinical consequences, OM has a significant economic impact, as the necessity of parenteral feeding, antibiotic therapy, control of pain and hospitalization significantly increases the costs of treatment. 2, 3, 6, 11, 21, 23 Despite the clinical and economic implications of OM, no effective therapy has been developed to date. Some interventions are successful, although most of them are palliative. Patients should be encouraged to maintain good oral hygiene and use antiinflammatory agents, antibiotics, topical anaesthetics and protective substances for the mucosa. Low-intensity laser therapy and the administration of epithelial growth factors are considered available resources in preventive interventions. However, they have high costs and require skilled staff. 2, 11, 21 The understanding of the pathogenesis of OM is essential to the development of new preventive and therapeutic alternatives. Oxidative stress and proinflammatory cytokines (such as TNF-a) are directly involved in mucosal destruction secondary to cancer treatment. Specifically, an increase in reactive oxygen species (ROS) occurs after radiation treatment or the administration of chemotherapeutic drugs with a subsequent number of events that cause direct tissue damage. Several studies have investigated the genes responsible for the control of ROS metabolism; the presence of deletion-specific nucleotide polymorphisms in a group of cancer patients was associated with a greater mucositis risk. A new approach to predict which patients will develop mucositis is the identification of certain single nucleotide polymorphisms (SNPs) using a genomewide association and candidate gene approaches. 24 Sonis et al. in 2004 proposed the theory of five stages of OM (Table 2) . Accordingly, its progression is seen not only as a result of direct cell damage but also as a series of complex biological events in the cells and tissues of the submucosa. [8] [9] [10] 25, 26 According to this proposal, it is suggested that the formation of ROS arising from the action of CT and RT would be capable of generating an oxidant-antioxidant imbalance and thereby activate proinflammatory cytokines responsible for tissue damage. Therefore, different strategies of prevention and treatment of OM have been aimed at the control of OS. 1, 4, 5, 7, 27, 28 Cannabidiol Cannabis sativa, popularly known as marijuana, is the most used illegal drug in the world and can be associated with many health problems. This plant contains over 545 substances, which have different effects in the body. More than 100 of them are classified as cannabinoids, and since the end of the nineteenth century, marijuana has been widely studied for medicinal use. 15, 29, 30 The term cannabinoid refers to a heterogeneous group of molecules that act on cannabinoid receptors present in the body. They can be produced endogenously, where anandamide (AEA) and 2-arachidonoylglycerol (2AG) are the endocannabinoids best known and studied to date. There are also derivatives in the plant known as phytocannabinoids such as delta-9-tetrahydrocannabidiol (THC) and CBD, or synthetic cannabinoids that are developed in the laboratory. 31 The two non-endogenous compounds most investigated are THC and CBD. It is known that limitations to the therapeutic use of THC stems from its capacity to cause psychoactive effects mediated through receptors in the central nervous system (CNS). CBD is totally devoid of psychoactive properties, due to the low affinity of these receptors for CBD, thus offering greater safety in clinical use. 12, 32 Cannabinoid receptors were identified in the 1980s and named by order of discovery, that is CB1 and CB2.
14 They are involved in the modulation of neuronal functions and inflammatory processes and in the aetiology of some diseases. Although CB1 and CB2 receptors share considerable structural similarities, they differ with regard to distribution and activity. CB1 receptors are located mainly in the CNS, peripheral nervous system and some organs, mediating effects on cognition, memory, motor performance and perception of pain. On the other hand, CB2 receptors are mainly expressed in the immune system and play an important role in the establishment of inflammatory processes, as they are involved in the reduction in proinflammatory cytokines. 14, 29, 33, 34 Thus, it is known that the type of receptor that has greater affinity for each compound is crucial to the resulting pharmacological effects.
Cannabidiol was isolated in 1942 and its molecular structure determined in 1963, and interest in its pharmacodynamics was only aroused after many years. To date, the mechanisms of action of CBD have not been fully elucidated, and the cell signalling pathways involved are still little known. In the last decade, there has been a substantial growth in medical studies on the application of CBD, mainly motivated by the discovery of its anti-inflammatory, antioxidant and neuroprotective activities. 14, 35, 36 Studies show that this compound is capable of suppressing the production of proinflammatory mediators through the suppression of cellular immune response, which can be important in the treatment of various diseases of inflammatory origin. Inhibition of adenosine uptake and decreased production of some inflammatory mediators such as IFN-c, TNF-a, IL-1b and IL-10 appear to be crucial in the anti-inflammatory action of CBD. 18 Many authors mention that the effect of CBD on OS can be more potent than that of classic antioxidants, such as a-tocopherol. A pioneer study conducted by Julius Axelrod and David Wink in 1998 showed that CBD was a potent neuroprotective antioxidant. The authors noted that there was a greater efficacy against glutamate-induced neurotoxicity than with ascorbate or a-tocopherol. This suggests that CBD has potential therapeutic application in neurodegenerative disorders associated with OS. 13, 17, 18, 33, [37] [38] [39] [40] [41] Rajan et al. evaluated the anti-inflammatory, antioxidative and anti-apoptotic effects of low doses of CBD. The results showed that 5 lM CBD had a moderate anti-inflammatory effect (TNF-a, IL-10) and oxidative markers (inducible nitric oxide synthase, nuclear factor erythroid 2-related factor 2, nitrotyrosine). Their in vitro results demonstrated the anti-inflammatory, antioxidant and antiapoptotic effects of CBD. 42 
DISCUSSION
An increase in FR, as evidenced by cell damage caused by CT and/ or RT, is capable of causing an imbalance in OS. This, in turn, stimulates the production of proinflammatory mediators responsible for tissue damage in OM. Thus, CBD could act both in the control of OS and the suppression of the inflammatory response, having a protective role against the development of OM. However, this hypothesis remains to be tested in a clinical and molecular setting, as we did not find specific studies covering this topic.
In the area of dentistry, only one experimental study of CBD was found, which was carried out in a rat model with induced periodontitis. After 30 days of treatment with 5 mg/kg CBD daily, morphological analysis of alveolar bone loss demonstrated that the animals treated with the compound exhibited a regional decrease Anti-emetic activity Cisplatin 2Á5 or 0Á5 mg Anti-emetic and antinausea effects by indirect activation of 5-HT receptor 49 Rock et al.
51
Prevention of nephrotoxicity Cisplatin 2Á5 or 10 mg Decrease in ROS and improvement in renal function. 12 Pan (2009) 12 Prevention of cardiotoxicity Doxorubicin 5 mg Decrease in proinflammatory cytokines, attenuation of decline in antioxidants and improvement in cardiac function. 50 Fouad et al.
52
Prevention of cardiotoxicity Doxorubicin 10 mg Decrease in cardiac dysfunction, improvement in cardiac mitochondrial function and decrease in oxidative stress. 32 Hao et al.
32
Prevention of neuropathic pain Paclitaxel 2Á5 or 10 mg Attenuation of pain without hampering treatment efficacy. 51 Ward et al.
53
CT/RT on oral mucosa in bone loss and a lower expression of NF-kB. Moreover, in the gingival tissue of the CBD-treated group, there was a decrease in neutrophil migration, with reduced production of interleukin-1b and TNF-a. 43 These results suggest that CBD may be useful in the control of inflammation caused by induced periodontal disease in rats. The possibility of searching for similar results in study models of OM can evaluate research in this area, aimed at obtaining favourable clinical effects.
A literature review of the use of cannabinoids in the management of chronic pain in dentistry was also found. The authors addressed the possibility of using CBD in the control of symptoms of burning mouth syndrome, neuralgia of the trigeminal nerve and post-herpetic neuralgia. On the basis of the proven involvement of the endocannabinoid system in analgesia, promising results in studies of pain of various aetiologies (Table 3 ) and of the mechanism of action of CBD, the authors suggested that this could be a potential therapeutic agent for the above disorders. The prospect of controlling pain with CBD can be another favourable way of managing OM. 30 In the United Kingdom, Canada and other countries, an oral spray containing 50% CBD (Sativex) can be legally prescribed for the purpose of relieving pain and spasticity associated with multiple sclerosis, which denotes the safety of its use in humans. 31, [41] [42] [43] [44] [45] ; However, an observational study in a limited sample with eight patients investigated the effects of oral use of this product. The most frequently reported findings were a burning sensation after application, dry mouth, halitosis and hyperkeratosis. However, the authors warned of the possibility of these results not being linked specifically to CBD but rather to the high concentration of alcohol in the product. 46 Even though we evaluated studies on CBD conducted in the medical area, the literature that supports the therapeutic potential of its use is still limited and lacks well-designed clinical studies, regardless of the disorder in question. Most findings are from in vitro or in vivo preclinical research and clinical cases. 34 There are several reports of the protective action of CBD in other disorders associated with the toxicity of anticancer therapy mediated by OS, as well as systemic effects that may be of interest, such as its antiemetic activity and ability to improve renal and cardiac function (Table 3 ).
Whereas Table 3 shows various events associated with the adverse effects of CT, the studies cited are mediated by OS as well as OM. On the basis of the favourable results of these studies, it can be proposed that CBD is capable of exerting some protective effect in oral tissues in the management of OM (Fig 1) . However, there is still a lack of consensus in the dose to be administered, which confirms the need for new studies that can establish doseresponse parameters.
A recent review of the literature concluded that medical marijuana has potential therapeutic applications in oncology, but the available evidence and legal status pose a challenge for physicians and oncology providers. There is moderate evidence for the use of cannabis in pain management. Some patients subjectively report benefit from cannabis for nausea, appetite, sleep and anxiety problems, but the level of published evidence remains low. Clinical trials are underway, but the legal status in some countries presents challenges to research. It is critical that oncology professionals are able to at least address the known risks and adverse effects of marijuana when questions arise from patients. Current available evidence is conflicting in terms of cancer risk. There is preliminary research on the anticancer effects of cannabis, which may balance out the risk to some extent. Overall, medical marijuana may have use in cancer care, but more research is needed to better inform physicians and patients. 47 As an alternative to treat complications of antineoplastic therapies, added to eventual beneficial effects, it is important to consider the interaction of CBD with tumoral cells. Risks and benefits of antioxidant agents for antineoplastic have been debated among oncologists, radiotherapists and other professionals. It is speculated that drugs able to protect healthy tissues could also protect tumour cells, jeopardizing regular treatment.
Recent studies point to CBD as a promising alternative to cancer treatment due to its ability to inhibit proliferation, adhesion, migration, invasion and angiogenesis of neoplastic cells. However, the molecular mechanisms involved in these properties are not well established and they depend on which neoplasm is to be treated and respective drug. 19, 48, 49 It is compulsory to further investigate CBD in the management of OM to unveil its actual potentiality.
WHAT IS NEW AND CONCLUSIONS
The lack of effective strategies for the prevention of OM has prompted researchers to investigate new therapeutic agents, in view of the serious consequences caused by this disease. Studies on the action of various types of antioxidant agents in the prevention of OM represent a significant part of current research regarding this disease, which could contribute to the better understanding of the biopathology of OM and of the role of FR in its development.
The antioxidant, anti-inflammatory and analgesic activity of CBD, along with its safety, are decisive factors in stirring interest in its use in dentistry. In view of the foregoing, we believe that studies should be encouraged in testing CBD in the treatment of difficult-to-manage oral diseases, such as OM. Its mechanism of action seems to involve functions that could play a positive role in the prevention and treatment of OM.
